StimCardio Closes Oversubscribed $30 Million Series A for Wearable Atrial Fibrillation Therapy
StimCardio, a Los Angeles, CA-based clinical-stage medical device company developing non-invasive wearable therapeutics for atrial fibrillation (AF), has announced the closing of its oversubscribed $30 million Series A financing led by Metis Medtech, with participation from Catalyst Health Ventures, multiple corporate strategic investors, and other new and existing investors. The financing is expected to fund StimCardio through its planned NeuroPulse 2 pivotal study and preparation for a De Novo submission to the U.S. Food and Drug Administration (FDA).
According to a 2025 analysis of Global Burden of Disease data published in the Journal of the American College of Cardiology, approximately 59 million people worldwide are living with AF. Catheter ablation is an established treatment recommended as a first-line rhythm control therapy for selected patients under the 2023 ACC/AHA/ACCP/HRS clinical guidelines, yet approximately 30% to 40% of patients experience recurrent AF following an initial ablation procedure despite advances in ablation technology, including pulsed field ablation. StimCardio’s lead investigational product, Rhyvive, is a wrist-worn therapeutic wearable designed to deliver personalized, non-invasive median nerve stimulation through a closed-loop system integrating physiological sensing and neuromodulation. Developed as an adjunct to catheter ablation, Rhyvive is designed to extend treatment beyond the procedure and into the patient’s home by modulating autonomic nervous system pathways with the goal of reducing recurrent atrial arrhythmias.
The financing follows presentation of StimCardio’s NeuroPulse 1 pilot study as a late-breaking clinical trial at HRX Live 2026 and its peer-reviewed publication in Heart Rhythm. The randomized, double-blind, sham-controlled study demonstrated a statistically significant reduction in recurrent atrial arrhythmia events post-ablation with active median nerve stimulation compared with the sham treatment group. NeuroPulse 2 will be a major, multicenter pivotal trial designed to evaluate whether adding wearable neuromodulation to catheter ablation improves clinical outcomes compared with ablation alone.
Amir Soltanianzadeh, CEO of StimCardio Medical, said the company’s vision is to establish non-invasive neuromodulation as a new therapeutic category in cardiac electrophysiology. Soltanianzadeh noted that the financing brings together investors with deep expertise in cardiac device innovation and provides the resources to deliver a first-of-its-kind, multicenter pivotal study, and that with encouraging clinical evidence to date and a growing research program, StimCardio sees an opportunity to extend treatment beyond the procedure room and improve outcomes for millions of people living with AF.
John Slump, CEO and founder of Metis MedTech and a StimCardio board member, said StimCardio is pioneering technology positioned to disrupt the cardiac electrophysiology arena. Slump noted that despite decades of advances in catheter ablation, AF recurrence remains a significant unmet clinical challenge, and that StimCardio’s non-invasive wearable represents an entirely different approach that the firm believes will redefine the treatment paradigm, reflecting strong conviction in the team, disruptive technology, and growing market.
Joshua Phillips, Managing Partner of Catalyst Health Ventures and a StimCardio board member, said Catalyst invests early in paradigm-shifting technologies with the potential to transform patient care. Phillips noted that StimCardio’s differentiated therapeutic approach targets a significant unmet clinical need affecting a large patient population, and that supported by encouraging early clinical evidence, the technology has the potential to reduce AF recurrence following catheter ablation.
